Stem-Cell Specialist iPierian Differentiates Its Programs, Spins Out True North Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Insider investors committed $30 million to support two separate companies, each aiming to file an IND within 18 months. South San Francisco-based iPierian will concentrate on a candidate with potential in Alzheimer’s disease and related tauopathies, while the newly spun-out True North will focus on a compound targeting the complement system.